Roschier represented Quest Diagnostics in its acquisition of Blueprint Genetics
Quest Diagnostics has acquired Blueprint Genetics from a number of private and entity sellers in an all-cash equity transaction. Roschier represented the buyer in the transaction.
Listed on the New York Stock Exchange, Quest Diagnostics, Inc is a world-leading provider of diagnostic information services. Quest specializes in combining state-of-the-art technologies, such as next generation sequencing, with higher-order interpretative expertise and digital customer enablement.
Blueprint Genetics Oy is a Finnish-based, specialty genetic testing company with broad expertise in gene variant interpretation based on next generation sequencing (NGS) and proprietary bioinformatics.
Together, Quest and Blueprint Genetics will broaden access to actionable insights in genetic and rare diseases, improving patient care and pharmaceutical drug research and development. Blueprint Genetics is expected to continue to operate largely independently from its base laboratory in Helsinki, with a presence in other countries.